USA flag logo/image

An Official Website of the United States Government

MEASUREMENT OF O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE IN HUMAN TUMORS

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
13737
Program Year/Program:
1992 / SBIR
Agency Tracking Number:
13737
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Applied Genetics, Inc.
205 Buffalo Ave Freeport, NY 11520
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1992
Title: MEASUREMENT OF O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE IN HUMAN TUMORS
Agency: HHS
Contract: N/A
Award Amount: $500,000.00
 

Abstract:

NITROSOUREAS ARE EFFECTIVE ANTITUMOR AGENTS, ESPECIALLY IN BRAIN CANCER. HOWEVER, TUMORS ARE OFTEN RESISTANT DUE TO ACTIVITY OF THE HUMAN DNA REPAIR ENZYME, O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE (O6MT). THE OUTCOME OF CHEMOTHERAPY MAY BE PREDICTED BY MEASURING THE LEVELS OF O6MT IN SINGLE CELLS FROM TUMOR BIOPSIES, AND A MORE RATIONAL TREATMENT REGIME MAY BE DESIGNED. THIS APPROACH IS NOW FEASIBLE BECAUSE OF THE CLONING OF THE HUMANO6MT GENE. THE PHASE I RESEARCH WILL USE POLYCLONAL ANTIBODIES AND DNA PROBES TO MEASURE O6MT LEVELS IN HUMAN TUMOR SAMPLES TAKEN AT INITIAL BIOPSY AND AT SECOND-LOOK SURGERY. THE IMMUNOHISTOCHEMICAL AND IN SITU HYBRIDIZATION ASSAY WILL BE DEVELOPED, AND TEST RESULTS WILL BE CORRELATED WITH PATIENT OUTCOME. THIS WILL ESTABLISH THE USEFULNESS OF THESE ASSAYS IN A CLINICAL TRIAL TO PREDICT DRUG RESISTANCE AND PATIENT RESPONSE TO TREATMENT.

Principal Investigator:

Daniel B Yarosh
5168689026

Business Contact:

Small Business Information at Submission:

Applied Genetics Inc.
205 Buffalo Ave Freeport, NY 11520

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No